CSIMarket
 
Relmada Therapeutics Inc   (RLMD)
Other Ticker:  
 
 
Price: $5.4200 $0.39 7.753%
Day's High: $5.53 Week Perf: -6.07 %
Day's Low: $ 4.80 30 Day Perf: -1.45 %
Volume (M): 195 52 Wk High: $ 7.22
Volume (M$): $ 1,054 52 Wk Avg: $3.28
Open: $4.97 52 Wk Low: $2.00



 Market Capitalization (Millions $) 163
 Shares Outstanding (Millions) 30
 Employees 11
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -112
 Cash Flow (TTM) (Millions $) -36
 Capital Exp. (TTM) (Millions $) 0

Relmada Therapeutics Inc
Relmada Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing novel therapies for the treatment of central nervous system (CNS) disorders. The company was founded in 2004 and is headquartered in New York, NY.

Relmada's lead product candidate is dextromethadone (d-Methadone), which is a new chemical entity designed to treat chronic pain in a way that avoids the potential for abuse and addiction. It is currently undergoing phase III clinical trials for the treatment of neuropathic pain associated with complex regional pain syndrome (CRPS). In addition, the company is developing other drug candidates aimed at addressing other CNS disorders such as depression, anxiety, and addiction.

Relmadaes approach to drug development focuses on optimizing the pharmacology of existing drugs rather than designing entirely new ones. This approach reduces the overall development time and costs while allowing the company to leverage existing clinical data and expertise.

The companyes drug development programs are based on intellectual property licensed from the University of Chicago, the Companyes co-founders, and from third-party licensors. Relmadaes proprietary technological platform enables the development of new chemical entities and the optimization of existing drugs' pharmacology.

Relmadaes team of experienced scientists, executives, and advisors have a track record of successful drug development and commercialization. The Companyes management team includes an Executive Chairman, CEO, and COO, and the board of directors includes high-level executives from the pharmaceutical industry.

In summary, Relmada Therapeutics Inc. is a clinical stage biopharmaceutical company that focuses on developing novel therapies for the treatment of CNS disorders, leveraging the optimization of existing drugs and a proprietary technological platform. The company's main drug candidate is d-Methadone, which is currently in Phase III clinical trials for the treatment of neuropathic pain associated with CRPS.


   Company Address: 2222 Ponce de Leon Coral Gables 33134 FL
   Company Phone Number: 629-1376   Stock Exchange / Ticker: NASDAQ RLMD
   RLMD is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Relmada Therapeutics Inc

Relmada Therapeutics Inc Reveals Recent Operating Shortfall of $-22.7 Million - What's Next for the Company?



Relmada Therapeutics Inc, a pharmaceutical company listed on the NASDAQ, has witnessed a notable surge in its stock value over the past trading days. Additionally, the company has shown positive advancements in its financial results, evident in the reduction of its operating shortfall and diminishing returns. These developments raise questions about how these factors will impact Relmada Therapeutics Inc moving forward and what it means for its competitiveness in the industry.
Stock Performance
Over the past five trading days, Relmada Therapeutics Inc's stock has experienced a solid gain of 5.69%. Furthermore, during the preceding 30 days, the company's stock recorded an increase of 5.33%. Although the stock is currently trading on the NASDAQ 3.4% below its 52-week average, the recent gains signify positive investor sentiment and confidence in the company's prospects.

Relmada Therapeutics Inc

Relmada Therapeutics Inc Makes Strides in Financial Performance, Narrowing Operating Shortfall to $-45.512072 million by Q2 2023

Relmada Therapeutics Inc, a major player in the pharmaceutical preparations industry, recently revealed disappointing financial figures for the second quarter of 2023. The company reported an operating shortfall of $-26.026726 million, which, although an improvement compared to the $-45.512072 million shortfall in the same quarter of the previous year, suggests that RLMD is still struggling to find its footing in the market.
While it is commendable that Relmada Therapeutics Inc has been actively working on developing new revenue sources, it is crucial for the company to prioritize running its operations in an economically efficient manner. It is apparent that RLMD has made efforts to cut down on losses, as the operating shortfall for the second quarter of 2023 decreased to $-25.303 million from $-39.935 million in the previous year's second quarter. However, these figures still indicate that the company is facing significant challenges.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com